|
Market Cap (25-Jun) $7,311,981 (1,468th) |
Close (30-Jun) $0.042 |
Volume (30-Jun) 582,113 |
Shortsold (6-Dec) 611,822 (0.21%) (374th) |
|
52w High $0.021 |
52w Low $0.009 |
P/E 11.60 |
EPS -0.01 |
ACR released this announcement to the ASX on 15 January 2021, 15:32. The announcement is not marked as price sensitive, and is 2 page(s) in length and 249.39kb in size.
You can view all announcements from ACR and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACR was 0.002% short sold according to ASIC data. It was ranked the 645th most shorted stock on the ASX. It is now ranked as the 374th most shorted stock on the ASX with 0.210% of total shares short sold as of the latest reported data (06 December 2024).
| Other Recent Announcements from ACR | |
|---|---|
| Appendix 3Y Brooke | 16 June 2023, 9:27 |
| Application for quotation of securities - ACR | 16 June 2023, 9:25 |
| 4th FDA ANDA approval received - Dapsone Gel, 5% | 7 June 2023, 10:35 |
| Change of Director's Interest Notice | 15 January 2021, 15:32 |
| Appendix 2A | 15 January 2021, 15:30 |
| Acrux Receives FDA Approval - Generic Testosterone Solution | 12 January 2021, 9:16 |
| Acrux Ltd Share Purchase Plan Offer Booklet | 8 January 2021, 8:24 |
You must be logged in to post a reply.
